Helix PartnersPopulation genetic screening efficiently identifies carriers of autosomal dominant diseasesJuly 27, 2022
Public HealthA Method for Variant Agnostic Detection of SARS-CoV-2, Rapid Monitoring of Circulating Variants, and Early Detection of Emergent Variants Such as OmicroNJune 29, 2022
Helix PartnersA pragmatic implementation research study for In Our DNA SC: a protocol to identify multi-level factors that support the implementation of a population-wide genomic screening initiative in diverse populationsApril 28, 2022
Helix PartnersHLA-A∗03:01 is associated with increased risk of fever, chills, and stronger side effects from Pfizer-BioNTech COVID-19 vaccinationApril 14, 2022
Public HealthSARS-CoV-2 variant Delta rapidly displaced variant Alpha in the United States and led to higher viral loadsMarch 15, 2022
Helix PartnersPositive predictive value highlights four novel candidates for actionable genetic screening from analysis of 220,000 clinicogenomic recordsAugust 12, 2021
Helix PartnersComprehensive allele genotyping in critical pharmacogenes reduces residual clinical risk in diverse populationsApril 30, 2021
Public HealthEmergence and rapid transmission of SARS-CoV-2 B.1.1.7 in the United StatesMarch 30, 2021
Public HealthGenomic epidemiology identifies emergence and rapid transmission of SARS-CoV-2 B.1.1.7 in the United StatesFebruary 6, 2021
Public HealthS gene dropout patterns in SARS-CoV-2 tests suggest spread of the H69del/V70del mutation in the USDecember 20, 2020
Helix PartnersPathogenic variants in actionable MODY genes are associated with type 2 diabetesOctober 11, 2020
Public HealthAutoantibodies against type I IFNs in patients with life-threatening COVID-19September 24, 2020
Public HealthInborn errors of type I IFN immunity in patients with life-threatening COVID-19September 24, 2020